LianBio Announces Departure of Chief Financial Officer
LianBio (Nasdaq: LIAN) announces resignation of CFO and appointment of Interim CFO
12/20/2023 - 08:00 AM
SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023.
In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer.
“We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role,” said Konstantin Poukalov, Executive Chairman of the LianBio Board of Directors.
About LianBio LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For additional information, please visit the company’s website at www.lianbio.com .
For investor inquiries, please contact: Elizabeth Anderson, VP Communications and Investor Relations E: elizabeth.anderson@lianbio.com T: (646) 655-8390
For media inquiries, please contact: Katherine Smith, Evoke Canale E: katherine.smith@evokegroup.com T: (619) 849-5378
Who resigned from LianBio and who was appointed as the Interim CFO?
Yi Larson, Chief Financial Officer, has resigned from LianBio and Ehong (Maggie) Gu, current VP, Head of Global Finance, has been appointed as Interim Chief Financial Officer.
When did the resignation of the CFO take effect?
The resignation of the CFO took effect on December 19, 2023.
What is the ticker symbol for LianBio?
The ticker symbol for LianBio is LIAN.
What is the focus of LianBio as a biotechnology company?
LianBio is dedicated to bringing innovative medicines to patients in China and other major Asian markets.
Who is the Executive Chairman of the LianBio Board of Directors?
Konstantin Poukalov is the Executive Chairman of the LianBio Board of Directors.
LIAN Rankings
#55 Ranked by Stock Gains
LIAN Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About LIAN
lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.